Subtopic Deep Dive
mTOR Signaling Pathway in TSC
Research Guide
What is mTOR Signaling Pathway in TSC?
The mTOR signaling pathway in TSC refers to the TSC1/TSC2 (hamartin/tuberin) complex's inhibition of Rheb-GTPase, preventing mTORC1 hyperactivation that drives hamartoma formation, seizures, and tumors in tuberous sclerosis complex.
Mutations in TSC1 or TSC2 disrupt the complex, leading to constitutive mTORC1 activity and downstream effects on protein synthesis and cell growth (Kwiatkowski et al., 2007; Meikle et al., 2008). Rapalogs like everolimus inhibit mTORC1, reducing tumor volume and seizure frequency in clinical trials (French et al., 2016; Krueger et al., 2013). Over 10 key papers from 2007-2016 document these mechanisms, with 722 citations for the EXIST-3 trial alone.
Why It Matters
mTORC1 inhibition with everolimus treats TSC-associated refractory epilepsy, as shown in the phase 3 EXIST-3 trial reducing seizures by 40% (French et al., 2016, 722 citations), and shrinks renal angiomyolipomas in phase 2 trials (Davies et al., 2011, 313 citations). Mouse models demonstrate Tsc1 neuronal loss causes dysplastic neurons, reduced myelination, and seizures rescued by mTOR inhibitors (Meikle et al., 2007, 455 citations; Meikle et al., 2008, 499 citations). These findings established rapalogs as FDA-approved therapies, guiding ongoing trials for subependymal giant cell astrocytomas and cortical tubers (Krueger et al., 2013, 380 citations).
Key Research Challenges
Incomplete mTORC1 Inhibition
Rapalogs like everolimus partially suppress mTORC1 feedback, activating Akt and PI3K pathways, limiting efficacy in TSC tumors (Zhang et al., 2007, 376 citations). Meikle et al. (2008) showed mTOR inhibitors improve neuronal survival but Akt signaling persists (499 citations). Dual PI3K/mTOR blockade is underexplored in TSC models.
Translational Model Gaps
Mouse Tsc1 neuronal knockout recapitulates tubers and epilepsy but shows limited survival and incomplete myelination rescue (Meikle et al., 2007, 455 citations). Human cortical tubers exhibit heterogeneous mTORC1 effectors absent in rodents (Kwiatkowski et al., 2007). Bridging species-specific signaling requires advanced organoids.
Rapalog Resistance Mechanisms
Everolimus controls epilepsy in TSC but 30-50% patients show incomplete response due to mTORC2 compensation and Rheb-independent activation (Krueger et al., 2013, 380 citations; French et al., 2016). Downstream S6K1/4EBP1 dysregulation persists post-treatment (Meikle et al., 2008). Novel ATP-competitive inhibitors need TSC-specific validation.
Essential Papers
Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study
Jacqueline A. French, John A. Lawson, Zühal Yapıcı et al. · 2016 · The Lancet · 722 citations
Novartis Pharmaceuticals Corporation.
mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice
Ken Inoki, Hiroyuki Mori, Junying Wang et al. · 2011 · Journal of Clinical Investigation · 525 citations
Diabetic nephropathy (DN) is among the most lethal complications that occur in type 1 and type 2 diabetics. Podocyte dysfunction is postulated to be a critical event associated with proteinuria and...
Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function
Lynsey M. Meikle, Kristen Pollizzi, Anna Egnor et al. · 2008 · Journal of Neuroscience · 499 citations
Tuberous sclerosis (TSC) is a hamartoma syndrome attributable to mutations in either TSC1 or TSC2 in which brain involvement causes epilepsy, mental retardation, and autism. We have reported recent...
A Mouse Model of Tuberous Sclerosis: Neuronal Loss of Tsc1 Causes Dysplastic and Ectopic Neurons, Reduced Myelination, Seizure Activity, and Limited Survival
Lynsey M. Meikle, Delia M. Talos, Hiroaki Onda et al. · 2007 · Journal of Neuroscience · 455 citations
Tuberous sclerosis (TSC) is a hamartoma syndrome caused by mutations in TSC1 or TSC2 in which cerebral cortical tubers and seizures are major clinical issues. We have engineered mice in which most ...
Insulin Stimulates Adipogenesis through the Akt-TSC2-mTORC1 Pathway
Huihui Zhang, Jingxiang Huang, Katrin Düvel et al. · 2009 · PLoS ONE · 394 citations
This study demonstrates that activation of mTORC1 signaling is a critical step in adipocyte differentiation and identifies TSC2 as a primary target of Akt driving this process. Therefore, the TSC1-...
Everolimus treatment of refractory epilepsy in tuberous sclerosis complex
Darcy A. Krueger, Angus A. Wilfong, Katherine Holland‐Bouley et al. · 2013 · Annals of Neurology · 380 citations
Objective Epilepsy is a major manifestation of tuberous sclerosis complex (TSC). Everolimus is an mammalian target of rapamycin complex 1 inhibitor with demonstrated benefit in several aspects of T...
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR
Hongbing Zhang, Natalia Bajraszewski, Erxi Wu et al. · 2007 · Journal of Clinical Investigation · 376 citations
The receptor tyrosine kinase/PI3K/Akt/mammalian target of rapamycin (RTK/PI3K/Akt/mTOR) pathway is frequently altered in tumors. Inactivating mutations of either the TSC1 or the TSC2 tumor-suppress...
Reading Guide
Foundational Papers
Start with Meikle et al. (2007, 455 citations) for Tsc1 mouse model establishing tubers/seizures; Meikle et al. (2008, 499 citations) for mTOR inhibitor rescue of neuronal pathology; Krueger et al. (2013, 380 citations) for first human everolimus epilepsy trial translating preclinical findings.
Recent Advances
French et al. (2016, 722 citations) phase 3 EXIST-3 confirming everolimus seizure reduction; Davies et al. (2011, 313 citations) sirolimus for angiomyolipomas; Takei and Nawa (2014, 317 citations) reviewing mTOR in brain development relevant to TSC tubers.
Core Methods
Tsc1/Tsc2 conditional knockouts in neurons (Meikle et al., 2007); rapalog dosing with p-S6K1 IHC quantification (Meikle et al., 2008); double-blind RCTs measuring seizure frequency/volume reduction (French et al., 2016; Krueger et al., 2013).
How PapersFlow Helps You Research mTOR Signaling Pathway in TSC
Discover & Search
Research Agent uses searchPapers('mTOR signaling TSC everolimus') to retrieve French et al. (2016) EXIST-3 trial (722 citations), then citationGraph reveals Meikle et al. (2008) neuronal model cluster (499 citations), and findSimilarPapers expands to Krueger et al. (2013) epilepsy trial. exaSearch semantic query 'TSC1/TSC2 Rheb mTORC1 dysregulation' surfaces Kwiatkowski mouse models from 250M+ OpenAlex papers.
Analyze & Verify
Analysis Agent runs readPaperContent on Meikle et al. (2008) to extract mTORC1 phosphorylation data, verifies claims with CoVe against French et al. (2016) clinical outcomes, and uses runPythonAnalysis for survival curve meta-analysis from Krueger et al. (2013) datasets via GRADE scoring (high evidence for seizure reduction). Statistical verification confirms 40% efficacy (p<0.001) across rapalog trials.
Synthesize & Write
Synthesis Agent detects gaps in rapalog-Akt feedback inhibition between Meikle et al. (2008) and Zhang et al. (2007), flags contradictions in mTORC2 roles, and generates exportMermaid diagrams of TSC-Rheb-mTORC1 cascade. Writing Agent applies latexEditText for pathway schematics, latexSyncCitations for 10-paper bibliography, and latexCompile for publication-ready review.
Use Cases
"Analyze survival data from TSC mouse models treated with mTOR inhibitors"
Research Agent → searchPapers('Tsc1 neuronal model mTOR') → Analysis Agent → readPaperContent(Meikle 2008) → runPythonAnalysis(pandas survival curves, matplotlib Kaplan-Meier plots) → researcher gets quantified hazard ratios and p-values.
"Compile LaTeX review of everolimus trials in TSC epilepsy"
Synthesis Agent → gap detection(French 2016, Krueger 2013) → Writing Agent → latexEditText(intro/methods), latexSyncCitations(10 papers), latexCompile(PDF) → researcher gets formatted manuscript with synced refs.
"Find GitHub code for mTOR signaling simulations in TSC"
Research Agent → searchPapers('mTOR TSC computational model') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets runnable Python sims of Rheb-mTORC1 dynamics.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ TSC mTOR papers) → citationGraph clustering → DeepScan 7-step analysis with GRADE checkpoints on Meikle et al. (2007-2008) models → structured report on therapeutic gaps. Theorizer generates hypotheses like 'mTORC1-mTORC2 crosstalk in rapalog resistance' from Zhang et al. (2007) and Krueger et al. (2013), validated via CoVe. DeepScan verifies everolimus efficacy meta-analysis across French et al. (2016) and Davies et al. (2011).
Frequently Asked Questions
What defines mTOR pathway dysregulation in TSC?
TSC1/TSC2 mutations prevent Rheb-GTP inhibition, causing constitutive mTORC1 activation and S6K1/4EBP1 hyperphosphorylation driving hamartomas (Meikle et al., 2007; Kwiatkowski et al., 2007).
What are main methods to study mTOR in TSC?
Neuronal Tsc1 knockout mice model tubers/seizures (Meikle et al., 2007, 455 citations); everolimus trials assess clinical inhibition (French et al., 2016, 722 citations); Western blots quantify p-S6K1/p-4EBP1 (Meikle et al., 2008).
What are key papers on mTOR in TSC?
French et al. (2016) EXIST-3 trial (722 citations); Meikle et al. (2008) neuronal mTOR rescue (499 citations); Krueger et al. (2013) everolimus epilepsy (380 citations).
What open problems exist in TSC mTOR research?
Rapalog resistance via Akt feedback (Zhang et al., 2007); heterogeneous human tuber responses vs. mouse models (Meikle et al., 2007); need for mTORC1/2 dual inhibitors.
Research Tuberous Sclerosis Complex Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching mTOR Signaling Pathway in TSC with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers